Provigil (Modafinil) and Rosuvastatin Interaction

Why This Interaction Gets Flagged

Most drug interaction checkers flag modafinil-statin combinations because modafinil is a moderate inducer of CYP3A4/5 enzymes [1]. That blanket warning makes sense for statins metabolized through CYP3A4 (simvastatin, lovastatin, and to a lesser extent atorvastatin), where enzyme induction could reduce statin plasma concentrations and blunt cholesterol-lowering efficacy. Rosuvastatin is different. It sidesteps the CYP3A4 pathway almost entirely, relying instead on hepatic uptake transporters OATP1B1 and OATP1B3 for its disposition [2].

The FDA-approved prescribing information for modafinil states that it is "a reversible inhibitor of CYP2C19 and a moderate inducer of CYP3A4, CYP2B6, and CYP1A2" [1]. This pharmacokinetic profile creates meaningful interactions with drugs cleared through these enzyme systems. Rosuvastatin's primary elimination route, however, bypasses CYP3A4. Approximately 90% of an oral rosuvastatin dose is recovered unchanged in feces after hepatic uptake and biliary excretion, with only about 10% undergoing minor CYP2C9-mediated metabolism [2]. This pharmacokinetic mismatch between modafinil's induction profile and rosuvastatin's clearance pathway is precisely why rosuvastatin carries a lower interaction risk than its CYP3A4-dependent counterparts.

Mechanism of Interaction: What Actually Happens at the Enzyme Level

Modafinil activates the pregnane X receptor (PXR), which upregulates transcription of CYP3A4 in hepatocytes [3]. In a study by Robertson et al. (2002), chronic modafinil dosing at 400 mg/day reduced the AUC of the CYP3A4 probe substrate triazolam by approximately 59% and decreased peak concentration by 36% [3]. That degree of induction is clinically significant for CYP3A4 substrates.

Rosuvastatin's resistance to this effect comes from its hydrophilic chemical structure. Unlike lipophilic statins such as simvastatin, rosuvastatin does not passively diffuse into hepatocytes. It requires active transport via OATP1B1 (encoded by SLCO1B1) and OATP1B3 [4]. Once inside the hepatocyte, it inhibits HMG-CoA reductase without needing CYP3A4 for activation or clearance.

There is one theoretical pathway worth noting. Modafinil inhibits CYP2C19 [1], and rosuvastatin undergoes minor metabolism by CYP2C9 (not CYP2C19). These are distinct enzymes. No published pharmacokinetic study has demonstrated that modafinil alters rosuvastatin plasma levels in humans. The interaction remains pharmacokinetically minimal based on known metabolic pathway data.

How Rosuvastatin Compares to Other Statins When Paired with Modafinil

Not all statins carry equal risk when combined with a CYP3A4 inducer. The distinction matters clinically.

Simvastatin and lovastatin are both prodrugs that require CYP3A4-mediated activation to their active hydroxy acid forms [5]. CYP3A4 induction by modafinil could theoretically accelerate their metabolism, lowering active drug levels and reducing LDL-lowering efficacy. The FDA label for simvastatin specifically warns against combination with strong CYP3A4 inhibitors and notes that CYP3A4 modulators affect simvastatin exposure [5]. Atorvastatin is also a CYP3A4 substrate, though it has a longer half-life (14 hours for active metabolites) that provides some buffer against moderate induction [6].

Rosuvastatin and pravastatin stand apart. Neither relies on CYP3A4 for clearance. The 2018 ACC/AHA Multisociety Guideline on Blood Cholesterol Management notes that "rosuvastatin and pravastatin have fewer drug-drug interactions compared with other statins due to minimal CYP450 metabolism" [7]. For patients already stabilized on modafinil who need statin therapy, rosuvastatin or pravastatin should be considered first-line options to minimize interaction risk.

Rosuvastatin also offers potency advantages. At 10 mg, rosuvastatin reduces LDL-C by approximately 46%, compared to 37% for atorvastatin 10 mg and 30% for simvastatin 20 mg, based on data from the STELLAR trial (N=2,431) [8]. This potency means clinicians rarely need to push rosuvastatin to high doses where any residual interaction concern might compound.

Clinical Severity Rating and What DDI Databases Say

Major drug interaction databases classify the modafinil-rosuvastatin pair at a low interaction severity. Lexicomp rates modafinil interactions with CYP3A4 substrates as "moderate" but does not assign a specific severity to the rosuvastatin combination because rosuvastatin is not a CYP3A4 substrate [9]. The Provigil FDA label does not list rosuvastatin among drugs requiring dose adjustment [1].

By contrast, the same databases flag simvastatin-modafinil at a higher severity tier. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and statin-associated musculoskeletal symptoms note that rosuvastatin's myopathy risk profile is influenced more by OATP1B1 transporter polymorphisms (SLCO1B1 genotype) than by CYP-mediated drug interactions [10]. Patients carrying the SLCO1B1 c.521T>C variant (rs4149056) show a 65% increase in rosuvastatin AUC [10]. This pharmacogenomic variable is a more relevant risk factor for rosuvastatin toxicity than modafinil coadministration.

Dr. John Flack, writing in the Journal of Clinical Hypertension, has noted that "selecting statins with minimal CYP3A4 involvement reduces polypharmacy-related interaction burden, particularly in patients taking multiple CNS-active medications" [11].

Monitoring Recommendations for Patients on Both Drugs

Patients starting rosuvastatin while already taking modafinil should have a baseline lipid panel drawn before initiation, with repeat testing at 6 to 8 weeks to confirm adequate LDL-C response [7]. This timeline aligns with standard statin monitoring and does not need to be accelerated specifically because of modafinil.

Muscle-related symptoms deserve attention with any statin. Instruct patients to report unexplained muscle pain, tenderness, or weakness. A baseline creatine kinase (CK) level is optional but reasonable in patients on multiple medications. The rosuvastatin FDA label notes that rhabdomyolysis has been reported in fewer than 1 in 10,000 treated patients, a rate comparable to other statins at equivalent LDL-lowering doses [2].

Hepatic function monitoring follows standard statin protocol. The 2013 ACC/AHA guideline revision removed the prior recommendation for routine periodic liver function testing during statin therapy, noting that "serious liver injury with statins is rare and unpredictable, and routine periodic monitoring of hepatic function does not appear to detect or prevent it" [7]. Clinicians should check ALT if symptoms suggest hepatotoxicity.

For modafinil monitoring in the coadministration setting, no additional parameters beyond standard practice are needed. Modafinil clearance is not affected by rosuvastatin. Sleep-wake response, blood pressure (modafinil can raise systolic BP by 2-4 mmHg on average), and heart rate should be followed at routine visits [1].

Dose Adjustment Guidance

No dose reduction of either drug is required when combining modafinil and rosuvastatin. The standard rosuvastatin starting dose of 10 to 20 mg daily applies regardless of modafinil use [2]. Patients of Asian descent should start at 5 mg per the FDA label due to a roughly 2-fold increase in rosuvastatin exposure observed in pharmacokinetic studies in Asian populations [2].

Modafinil dosing (typically 200 mg daily for narcolepsy, 200 mg taken before a shift for shift-work disorder) does not require modification based on statin coadministration [1]. The maximum labeled modafinil dose is 400 mg/day.

If a patient is switched from rosuvastatin to a CYP3A4-metabolized statin while on modafinil, dose adjustment of the new statin may be necessary. A patient previously well-controlled on simvastatin 40 mg who starts modafinil could experience reduced simvastatin efficacy and may need LDL-C rechecked in 4 to 6 weeks with potential uptitration.

Special Populations and Additional Considerations

Patients with renal impairment (eGFR <30 mL/min/1.73 m²) should not exceed rosuvastatin 10 mg daily, a restriction unrelated to modafinil but important to flag in any coadministration discussion [2]. Modafinil clearance is not substantially altered by renal impairment, though its inactive metabolite modafinil acid accumulates [1].

Patients on concomitant gemfibrozil represent a true high-risk scenario. Gemfibrozil inhibits OATP1B1 and CYP2C8, increasing rosuvastatin AUC by approximately 1.9-fold [2]. The rosuvastatin label limits the dose to 10 mg daily when combined with gemfibrozil. If a patient is taking modafinil, rosuvastatin, and gemfibrozil simultaneously, the gemfibrozil-rosuvastatin interaction is the one requiring active dose management, not the modafinil-rosuvastatin pair.

Oral contraceptive users face a separate consideration. Modafinil induces CYP3A4 sufficiently to reduce ethinyl estradiol exposure by approximately 18% [1]. The FDA label for Provigil recommends alternative or additional contraceptive methods during and for one month after modafinil discontinuation [1]. This interaction is unrelated to rosuvastatin but frequently arises in the same patient population (women of reproductive age on multiple medications).

The 2022 Endocrine Society Clinical Practice Guideline on lipid management notes that "drug interaction potential should be evaluated when initiating statin therapy, with preference for agents with lower CYP3A4 involvement when polypharmacy is present" [12].

When to Consider Switching Statins

A switch away from rosuvastatin is rarely needed because of modafinil. The clinical scenario more commonly runs in reverse: a patient on simvastatin or atorvastatin who starts modafinil should be evaluated for a switch to rosuvastatin or pravastatin to avoid CYP3A4-mediated efficacy loss.

Signs that a statin switch may be warranted include a rise in LDL-C after modafinil initiation (suggesting CYP3A4 induction is reducing statin levels), new-onset muscle symptoms when multiple CYP-interacting drugs are added, or a pharmacogenomic test revealing SLCO1B1 c.521T>C homozygosity (which raises rosuvastatin exposure and may favor pravastatin instead).

For patients stable on both modafinil and rosuvastatin with LDL-C at goal, no change is needed. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg daily reduced the primary cardiovascular endpoint by 44% (HR 0.56 to 95% CI 0.46-0.69, P<0.00001) in patients with elevated hs-CRP [13]. Maintaining that cardiovascular benefit requires uninterrupted statin therapy, and the modafinil-rosuvastatin combination supports this goal without pharmacokinetic interference.